Welcome to our dedicated page for Enhabit SEC filings (Ticker: EHAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Enhabit, Inc. (NYSE: EHAB) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as a public issuer. Enhabit, which operates as Enhabit Home Health & Hospice, files reports with the U.S. Securities and Exchange Commission that describe its home health and hospice business, financial performance, governance matters, and executive compensation arrangements.
Through its Form 8-K filings, Enhabit reports material events such as quarterly earnings releases, participation in investor conferences, leadership changes, and stockholder meeting results. For example, the company has filed 8-Ks to furnish its earnings press releases and supplemental information for quarters ended March 31, June 30, and September 30, as well as to describe a CEO transition plan, retention awards for senior officers, and approval of the Enhabit, Inc. 2025 Equity and Incentive Compensation Plan at its annual meeting.
Enhabit’s filings also identify its common stock as registered under Section 12(b) of the Exchange Act and traded on the New York Stock Exchange under the symbol EHAB. The company uses its SEC reports to explain its use of non-GAAP measures such as Adjusted EBITDA, Segment Adjusted EBITDA, Adjusted EPS, and Adjusted free cash flow, and to discuss how unusual or nonrecurring items affect the reconciliation to GAAP results. Same-store comparison methodology for home health and hospice locations is also described in these materials.
On this page, users can review Enhabit’s SEC filings in chronological order, including 8-Ks that detail results of operations and financial condition, regulation FD disclosures, equity plan approvals, and stockholder voting outcomes. Stock Titan’s tools surface these documents alongside AI-powered summaries that highlight key points, helping readers quickly understand how each filing relates to Enhabit’s home health and hospice operations, capital structure, and governance.
Investors and researchers can use this filings archive to follow Enhabit’s reported net service revenue trends, segment performance, executive and director arrangements, and the regulatory context around its home-based care business, all sourced from the company’s official submissions to the SEC’s EDGAR system.
Enhabit, Inc. reports progress on its pending sale to Kinderhook-affiliated funds. The U.S. Federal Trade Commission granted early termination of the Hart-Scott-Rodino antitrust waiting period on April 15, 2026, removing a key regulatory closing condition.
The special meeting of stockholders to vote on the merger with Anchor Parent, LLC is scheduled for May 12, 2026 at 8:00 a.m. Central Time. The company expects the merger to close in the second quarter of 2026, subject to remaining conditions, and is suspending earnings calls, guidance and a second-quarter 2026 earnings release while the transaction is pending.
Enhabit, Inc. is asking stockholders to approve a merger under which Anchor Parent, LLC (affiliates of funds advised by Kinderhook) will acquire Enhabit and convert each outstanding share into $13.80 in cash. The Board unanimously recommends approval and notes the Per Share Amount represents a roughly 33.8% premium to the 60-day VWAP prior to announcement.
The Special Meeting will be held virtually on May 12, 2026; the Record Date for voting is April 13, 2026 (51,225,606 shares outstanding as of that date). If approved and closed, Enhabit common stock will be delisted and deregistered and holders will receive cash (appraisal rights under Delaware law are available under specified procedures).
Enhabit, Inc. director Barry P. Schochet received an equity grant of 1,698 deferred stock units of Common Stock valued at $13.99 per unit. These units were taken instead of a cash retainer fee under the Enhabit, Inc. Deferred Director Compensation Plan.
After this award, Schochet directly holds 71,930 shares or units tied to Enhabit common stock. This is a routine, compensation-related acquisition rather than an open-market purchase or sale, and does not by itself signal a change in his investment view.
Enhabit, Inc. director Gregory S. Rush received a stock-based compensation award. On this Form 4, he acquired 1,787 shares of Enhabit common stock at $13.99 per share as a grant under the Enhabit, Inc. Deferred Director Compensation Plan in lieu of a cash retainer fee. Following this award, he directly holds 80,338 shares of Enhabit common stock.
Enhabit, Inc. director Stephan Rodgers received a grant of 1,340 shares of common stock-equivalent deferred stock units at a reference value of $13.99 per share. These units were acquired in lieu of a cash retainer fee under the Enhabit, Inc. Deferred Director Compensation Plan, bringing his directly held common stock and units to 21,338 shares after the transaction.
Ohlendorf Mark W reported acquisition or exercise transactions in this Form 4 filing.
Enhabit, Inc. director Mark W. Ohlendorf received an equity-based compensation award in the form of deferred stock units of common stock. The grant covered 1,340 units valued at $13.99 per unit, elected in lieu of a cash retainer fee under the Enhabit, Inc. Deferred Director Compensation Plan. Following this award, Ohlendorf directly holds 45,867 shares of Enhabit common stock.
MCGUIGAN STUART M reported acquisition or exercise transactions in this Form 4 filing.
Enhabit, Inc. director Stuart M. McGuigan received an equity-based award in the form of 1,340 shares of common stock valued at $13.99 per share. These are deferred stock units granted instead of a cash retainer fee under the company’s Deferred Director Compensation Plan.
After this grant, McGuigan directly holds 75,466 shares of Enhabit common stock. This transaction reflects routine director compensation rather than an open-market purchase or sale.
Hoeflinger Erin reported acquisition or exercise transactions in this Form 4 filing.
Enhabit, Inc. director Erin Hoeflinger received an equity-based compensation grant in the form of 1,698 deferred stock units of common stock. The units were credited at a reference price of $13.99 per share in lieu of a cash retainer fee under the Enhabit, Inc. Deferred Director Compensation Plan.
Following this grant, Hoeflinger directly holds 80,405 shares of Enhabit common stock. This is a routine director compensation award rather than an open-market share purchase.
Enhabit, Inc. director Charles M. Elson received an equity grant valued in stock rather than cash. On this Form 4, he acquired 1,340 shares of Common Stock-equivalent deferred stock units at $13.99 per share in lieu of a cash retainer fee under the Enhabit, Inc. Deferred Director Compensation Plan.
Following this award, Elson directly holds 80,638 shares of Enhabit common stock, reflecting his updated post-grant position as reported in the filing.
Enhabit, Inc. director Jeffrey Bolton acquired 2,680 shares of common stock-valued deferred stock units at $13.99 per unit as compensation. The units were received in lieu of a cash retainer fee under the Enhabit, Inc. Deferred Director Compensation Plan. Following this grant, Bolton directly holds 139,682 common shares-equivalent units.